Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
LeukemiaJul 17, 2026 (epub)
Max S Topp, Bijal D Shah, Elias Jabbour et al.
✦ AI-curated · Sources linked
In 30 seconds
The FELIX study evaluated the efficacy of obecabtagene autoleucel (obe-cel) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) compared to historical controls. This Phase Ib/II trial found that obe-cel achieved a significantly higher overall remission rate of 67.3% versus 51.4% for non-CAR T-cell therapies (p = 0.0257), indicating its potential as a superior treatment option.
Key findings
- Obe-cel achieved an overall remission rate of 67.3% compared to 51.4% for non-CAR T-cell therapies.
- Median overall survival was longer with obe-cel at 15.1 months versus 7.0 months (p = 0.0015).
- Event-free survival was significantly improved with obe-cel, median 9.8 months compared to 2.5 months (p < 0.0001).
- Safety profiles were comparable, with similar rates of Grade ≥3 adverse events.
Why it matters
This study highlights the potential of obe-cel to improve remission rates and survival in a challenging patient population, addressing significant unmet needs in the treatment of adult relapsed/refractory B-ALL.